Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883499 | 0.81 | HTR7 (0.33) | ALDH1A1GAA | |
| SCHEMBL27225059 | 0.74 | DAO (0.34) | — | |
| SCHEMBL31129470 | 0.72 | CRBN (0.41) | ALDH1A1 | |
| SCHEMBL31129331 | 0.70 | — | — | |
| SCHEMBL31111886 | 0.69 | MAPT (0.42) | ALDH1A1GAA | |
| SCHEMBL26447774 | 0.68 | NR3C1 (0.33) | — | |
| SCHEMBL31129698 | 0.68 | CSNK2A2 (0.47) | ALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL31129714 | 0.68 | CSNK2A2 (0.47) | ALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29482987 | 0.68 | GAA (0.41) | ALDH1A1GAA | |
| SCHEMBL20231862 | 0.68 | GAA (0.41) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | ALDH1A1 3651/4885GAA 721/4885CSNK2A2 2296/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | ALDH1A1 3268/4885GAA 2853/4885CSNK2A2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.